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1. Introduction
Background of NEXT Bioinformatics
National Experimental Therapy Partnership (NEXT) is a public-private part-
nership in clinical research comprising the regions of Denmark, Danish uni-
versities, 12 pharmaceutical companies, and one GTS institute. In addition, 
NEXT has several associated partners. The partnership was established on 
November 1, 2014, as an INNO+ partnership. Innovation Fund Denmark in-
vested DKK 50 million in the partnership over a five-year period, and the 
partners invested DKK 114 million. NEXT’s objective is to make Denmark the 
pharmaceutical industry’s first choice for early clinical trials of new drugs for 
patients, with a focus on proof-of-concept trials. NEXT aims to optimize all 
processes from the start-up to close-out of clinical trials, and the optimization 
of legal and regulatory processes is highly prioritized. 
The detection of cancer that is refractory to standard therapy using molecular 
biomarkers and the selection of candidates for early-phase clinical trials is 
becoming more and more important. Many of these methods are based on 
small gene panels that vary from one cancer type to another. These genomic 
analyses are not cost effective and it is difficult to systematize achieved know-
ledge. NEXT Bioinformatics was established as a part of NEXT to optimize the 
process of extensive genomic profiling (whole exome (DNA) and transcripto-
me (RNA) sequencing) for drug resistance detection and to make Denmark 
attractive for clinical trials. NEXT invested DKK 5 million in this initiative and 
the partners invested an additional DKK 5 million. 
NEXT Bioinformatics is based at the Cancer Data Science Laboratory of Aal-
borg University Hospital (Aalborg UH) and Aalborg University (AAU), and is 
coordinated by Professor Martin Bøgsted. NEXT Bioinformatics also consists 
of the Center for Genomic Medicine at Rigshospitalet (RH), the Department 
of Clinical Genetics, Odense University Hospital (OUH), the Department of 
NATIONAL EXPERIMENTAL 
THERAPY PARTNERSHIP
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Molecular Medicine, Aarhus University Hospital (AUH), and the Department 
of Pathology of Herlev University Hospital (HUH).
NEXT Bioinformatics has established a network of leading bioinformatics 
experts in Denmark who focus on precision medicine in oncology and hae-
matology by generating, validating, and implementing common standards for 
patient classification based on genome analyses. NEXT Bioinformatics is inter-
nationally competitive and an attractive collaboration partner for companies 
due to its close affiliation with the clinic.
What problems did NEXT Bioinformatics try to sol-
ve?
Before NEXT Bioinformatics was founded, bioinformaticians worked in small 
groups at the university hospitals in Denmark on their local bioinformatics 
workflows, computer systems, and data storage solutions, leading to inhomo-
geneous data storage across the nation, a lack of overview and a lack of a 
direct link between bioinformatics analyses and clinical users. The need to 
establish a network of bioinformaticians dedicated to harmonizing the work 
was evident. Moreover, there was a need to aid biomarker discovery of drug 
resistance based on material from Danish biobanks. Finally, as many biomar-
ker detections are not stored in searchable databases, there is a barrier to 
their usage in trial design and recruitment. To solve these issues, the strategy 
of NEXT Bioinformatics was to harmonize bioinformatics workflows across 
Denmark, cross-fertilize biomarker development, and establish a searchable 
database of detected variants. 
What solutions did NEXT Bioinformatics arrive at?
A start-up meeting was held March 2015 in Aalborg, where the network of Da-
nish clinical bioinformaticians was created and coined NEXT Bioinformatics. 
The group immediately began to develop common guidelines for bioinforma-
tics workflows. Subsequently, there were nine workshops at which the status 
of the work was discussed and the developed biomarkers were presented for 
mutual inspiration.  
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During the project, a variant database based on the findable, accessible, in-
teroperable, and reusable (FAIR) principles was established, which is now in 
use in the North Denmark Region and is underway in the rest of the country. 
The work of NEXT Bioinformatics has had great impact on clinical bioinforma-
tics in Denmark, as we now rely on harmonized workflows and have outlined 
searchable databases. The knowledge in the database is now utilized at Aal-
borg UH and is being used as inspiration for development of databases in the 
Danish National Genome Center. 
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2. Network activities
Workshops
Half-yearly workshops held during the project period:
Start-up meeting: NEXT Interdisciplinary Bioinformatics Activity meeting
March 3, 2015, Aalborg University Hospital, Aalborg
Workshop #1: Classification and in vitro models
August 26, 2015, Odense University Hospital, Odense
Workshop #2: CUP Classifiers
September 30, 2015, Aarhus University Hospital, Aarhus
Workshop #3: DNA-based technologies in personalized medicine and data 
management
January 26, 2016, Rigshospitalet, Copenhagen
Workshop #4: NEXT Database
May 27, 2016, Aarhus University Hospital, Aarhus
Workshop #5: Status, plan, and deliverables
November 23, 2016, Aalborg University Hospital, Aalborg
Workshop #6: Status, plan, and deliverables
May 19, 2017, Odense University Hospital, Odense
Workshop #7: Focal points of NEXT Bioinformatics
November 23, 2017, Rigshospitalet, Copenhagen
Workshop #8: NEXT Activity report
May 28, 2018, Aarhus University Hospital, Aarhus
Workshop #9: NEXT Activity report and perspectives
November 12—13, 2018, Klitgården, Skagen
Minutes of the meetings can be obtained upon request from the secretariat.
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3. Common standards for 
 bioinformatics workflows
To ensure consistency of results from high throughput sequencing (HTS) 
analyses of cancer patients across the country, and thus consistent clinical 
recommendations, there is a need to develop common standards for bioin-
formatics processing of raw data. A bioinformatics pipeline consists of many 
different steps of quality control, alignment, and calibration of the raw data 
before the final inference of somatic variants can be performed. A variety of 
different tools for calling somatic variants have been developed and many of 
these have been compared in terms of the speed and accuracy.1 Due to the 
abundance of different tools, building a pipeline is a complex endeavour if all 
possibilities are considered, so commercial solutions that offer pre-packaged 
pipelines are sometimes preferred, but many choose to rely on the Genome 
Analysis Toolkit (GATK) best practicesa. The GATK is a set of freely available 
bioinformatics tools with a high level of documentation and support and an 
accompanying set of best practices for optimal processing of HTS data. It is 
widely used, notably in the major American cancer sequencing repository, 
the Genomic Data Commons (GDC) and was already in use by the groups that 
formed the NEXT Common Standards, so it served as the starting point for the 
collaboration.
NEXT Common Standards
To develop the NEXT Common Standards, it was decided to initially focus on 
the calling of somatic single nucleotide variations and small insertions and 
deletions based on DNA-seq data, as these are the most widely used targets 
in HTS-based precision cancer medicine. Local adaptions of the GATK best 
practices at the participating departments where mapped out, showing that 
main differences were versions of reference files and genomes, so a common 
ground based on the GDC HG38 reference genome was agreed upon. Due to 
some pitfalls in the somatic variant calling performed by the Mutect2 tool in-
a Van Der Auwera et al. (2014) Curr Protoc Bioinformatics 11:1110; https://software.broadinstitute.
org/gatk/best-practices/
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cluded with the GATK, a second variant caller, Varscan2, was added, and a set 
of custom filters was included to join and filter the output. These recommen-
dations for the common standards and scripts that can be used as building 
blocks in a bioinformatics pipeline are described in more detail in a report 
documenting the results of this effort. The participating groups collaborated 
on this report via the GitHub web-based version control service, and it can be 
found at: https://github.com/NEXTBioinformatics/Best-Practices-for-Proces-
sing-HTS-Data
 
Figure 3.1: Front page of best practices home page.
Implementation
It was decided that all variants stored in the NEXT variant database, descri-
bed below, should be processed following the common standards, but since 
some local pipelines have been accredited for clinical use, they have not been 
changed. The added variant caller and custom filters are based on experien-
ces from the Department of Molecular Medicine at Aarhus University Ho-
spital (AUH), so their pipeline bears a strong resemblance to the common 
standards and they have been cited in a work utilizing this approach.2 The 
bioinformatics pipeline at the Department of Haematology at Aalborg UH was 
developed in parallel with the NEXT Common Standards and is based on the 
principles therein. A scientific paper describing the full workflow is currently 
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in preparation�3 The experiences and recommendations from the NEXT com-
mon standards may serve as a starting point for building a common Danish 
bioinformatics pipeline for inferring somatic variants at the Danish National 
Genome Centre.
Future directions
Although the focus of this working group was somatic variants based on DNA-
seq data, there has also been discussion of utilizing RNA-seq data to infer ad-
ditional information on dysregulated genes in tumours and larger structural 
variants. These methods are generally less standardized and the participating 
centres have different aims, but the work was also documented on the GitHub 
repository. Future work could involve standardizing these workflows across 
the different centres, and development of methods for detection of over- or 
underexpressed genes in single samples based on RNA-seq data is also highly 
relevant. This could be accomplished by forming a reference database of nor-
mal expression of genes in different tissues for healthy Danish individuals. Ad-
ditional information on copy number variation can also be derived from DNA-
seq data. This is already done at individual centres and is used for treatment 
guidance in some instances, but there is no standardization across the coun-
try. Finally, there is ongoing work on standardizing workflows for detecting 
microsatellite instability and tumours with high tumour mutational burden, 
which will aid in identifying patients who might benefit from immunotherapy. 
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4. Biomarker stratification of  
 patients
The development of prognostic and predictive biomarkers based on extensive 
genomic profiling has a great potential in Denmark due to our extensive bio-
banking facilities and electronic health records. Bioinformaticians contribute 
to all aspects of this work, from development of new biomarkers for functio-
nal studies to implementation of biomarkers for clinical use. This underscores 
the importance of fostering the education, training, and retention of clinical 
bioinformaticians to support the Danish potential to be a key player in can-
cer treatment. NEXT bioinformaticians have participated in all phases of such 
work over the funding period. Below, we briefly review the work to illustrate 
the impact of the contributions from NEXT.
Sub-classification of cancers by machine learning 
methods
NEXT bioinformaticians developed a number of cancer sub-classification tools 
based on high dimensional molecular signatures using various contemporary 
machine-learning methods. There has been great interest in classifying the 
tissue of origin of cancers of unknown primary (CUP), as this may potentially 
identify possible drug targets. Based on discriminant analysis, RH developed 
an RNA-classifier based on microarray data.4 This classifier has been further 
developed by AUH to include RNA-seq data and a combination of DNA-seq 
and RNA-seq data, based on restricted multinomial regression techniques,5 
showing that it is possible to identify the original tissue.
Aalborg UH worked with the hypothesis that cancer can be seen as a disease 
of differentiation by identifying the cell of origin of the cancer for a number 
of haematological malignancies.6–10 Their technology is based on restricted 
multinomial regression techniques with elastic net penalty. They show that 
the identified origin has prognostic value and treatment predictive potential. 
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OUH and University of Southern Denmark (SDU) has used archived material 
and support vector machines to predict the risk of recurrence of low-risk 
breast cancer and differential diagnosis between thrombocythemia and early 
prefibrotic myelofibrosis.11–14 In addition, RH has participated in further cha-
racterization of basal-like breast cancer.15
Systems biology and functional studies
Biomarker discovery is often conducted by class comparisons of genome-wide 
profiling of genetic variants and gene and protein expressions. Careful corre-
ctions for multiple testing are recommended, and the risk of false positives 
and spurious correlations is high. Stronger evidence is therefore sought by in 
silico systems biology studies and in vitro and in vivo functional studies. NEXT 
bioinformaticians have contributed to a number of systems biology and func-
tional studies over the project period. 
NEXT bioinformaticians have been involved in the development of system bio-
logical tools for pathway mining and applications, notably within breast can-
cer and haematological malignancies.8,9,16–19 NEXT bioinformaticians have also 
been involved in glioblastoma invasion modelling.20
At the Department of Haematology of Aalborg UH, extensive drug screens 
have been conducted on immortal cell lines originating from haematological 
cancer patients. These screens have been used to stratify them into sensiti-
ve, intermediate, and resistant groups. Differential analyses have been con-
ducted to identify differences in microRNA, gene, and protein expressions 
between the subgroups. Such differences have been used to build molecular 
signatures of prognostic significance and potential treatment resistance iden-
tification. This work has led to a number of in vitro lentiviral transduction stu-
dies to identify the potential of microRNA as a predictor of cytotoxic response 
potential�21
Implementation for clinical use
A clear advantage of a close collaboration between Danish bioinformaticians 
is that it accelerates the clinical implementation of new algorithms based 
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on molecular biomarkers. A prominent example is the CUP classification de-
scribed above, which is now in use in clinical protocols at AUH and RH.22,23 
The cell of origin and resistance classifiers are now being validated in clini-
cal protocols at Aalborg UH. RH has worked to make the pipelines clinically 
useful in phase 1 studies.24,25 NEXT Bioinformatics is currently developing a 
fast platform for implementing new genome-wide tools in clinical applicati-
ons. Notable examples include NGS-derived tools for calculation of tumour 
mutational burden and microsatellite instability for use in allocation of im-
munotherapies. Tools for assessing the clinical relevance of identified somatic 
variants have been discussed and developed to aid genome interpreters and 
physicians in their clinical work. Furthermore, RH has studied the potential of 
following cancer development by ctDNA.26
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To search for and recruit patients more efficiently, a platform was built to col-
lect clinical and genomic information about patients at participating centres 
in Denmark.
In addition to patient recruitment, the platform has three other goals, to 
provide a good estimate of potential cohort size based on precise inclusion 
criteria, foster academic research in the field, and act as a prototype for a 
precision cancer decision support tool.
Platform
Developed at Aalborg UH, the platform is currently hosted on an Ubuntu 
16.04 server at the North Denmark Region’s datacentre, which is tier 4-cer-
tified. To facilitate its deployment to other hosting solutions, the platform 
is packaged in a Docker 17.12 containerb. The platform was developed using 
Python 3.5c, a data-science friendly software language, with a state-of-the-art 
web framework, Django 2.1d and is connected to a Microsoft SQL server 12.0 
database. It features access control mechanisms based on roles and centres 
as well as audit trails. The front-end of the platform was developed in HTML 
5, CSS 3 and javascript 1.8 with jQuery 3.2e using the Bootstrap 4.1 front-end 
component libraryf. There was a focus on user experience to make it accessi-
ble for people with potentially limited informatics skills.
Data collection
The principle of the platform is to combine clinical and genomic data and 
interpretations to make it as relevant as possible for pharmaceutical compa-
nies, researchers, and clinicians.
a 
b https://www.docker.com/
c https://www.python.org/
d https://www.djangoproject.com/
e https://jquery.com/
f https://getbootstrap.com/
5. Variant database
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Clinical data
The clinical data are stored in a manner that facilitates visualization of the 
patient trajectory. Every patient is registered with an anonymized identifier, 
date of birth, and gender. Each patient belongs to a centre and members of 
the centre can only see the corresponding data. For every patient, multiple 
cases can be created, and a case is defined as a primary cancer or relapse. 
Each case is described by an International Classification of Disease, Version 
10 (ICD-10) diagnosis code, a diagnosis date, an International Classification of 
Disease for Oncology, Version 3.1 (ICD-O-3.1) morphology code, an ICD-O-3.1 
topography code, relapse number, treatment regimen, status with a date, and 
Easter Cooperative Oncology Group (ECOG) performance status. In the con-
text of a precision cancer medicine research project implemented at Aalborg 
UH, data are collected using REDCap and utilities were developed to synchro-
nise the data automatically through application programming interface (API) 
calls.
 
Figure 5.1: Overview of patients in the platform.
Genomic data and annotations
For each case, multiple genomic files can be uploaded to the platform. These 
files are grouped by sample. Samples are defined by an identifier, a sampling 
date and a tissue type, allowing for storage of information from samples over 
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multiple locations and monitoring of samples over time. The database cur-
rently supports Variant Call Format (VCF) files for Single Nucleotide Variants 
(SNVs) and insertions-deletions (indels). The Human Genome Variation Socie-
ty (HGVS) nomenclature is used to uniquely identify variants and is genera-
ted by the Variant Effect Predictor (VEP). The VEP also provides annotations 
such as the allele frequency in the general population and the impact of the 
variants on the corresponding protein. Future plans include the support of 
Structural Variations (SVs) including fusions, Copy Number Variations (CNV) 
and translocations.
 
Figure 5.2: Overview of detected variants.
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Interpretation
To advance the understanding of genomic data, efforts have been made to 
support interpretations generated with Qiagen Clinical Insights (QCI), such 
as prognosis impacts, targeted treatments, and clinical trials. In addition, we 
plan to integrate data from the Precision Medicine Knowledge Base (PMKB) 
and Precision Oncology Knowledge Base (OncoKB) to generate a default set of 
interpretations for centres that do not use QCI.
Figure 5.3: Example of annotations of variants.
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Variant search
A variant search interface was built to allow for searching for patients across 
centres based on genomic and clinical data. This functionality can be used 
to search for patients to be included prospectively or to estimate potential 
cohort sizes retrospectively for pharmaceutical companies to scale their cli-
nical trials. However, detailed information about the cases is only available to 
centres that entered data in the platform, giving them tight control of how 
these data are shared.
 
 
Figure 5.4: The search interface.
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Precision Cancer Medicine report
By combining interpreted genomic data with clinical data, the platform makes 
it possible to generate Precision Cancer Medicine (PCM) reports to be used 
in genomic multidisciplinary team (MDT) evaluations. The idea is to provide 
external clinicians with an overview of the patient trajectory to allow for a 
better overall understanding of the patient’s situation. A PDF version of the 
report can be generated on demand for printing and archiving.
 
Figure 5.5: Example of tumour board report.
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6. Discussion
Main results of NEXT Bioinformatics 
Supported by DKK 10 million from the NEXT initiative, NEXT Bioinformatics 
has facilitated an interactive network of clinical bioinformaticians across Da-
nish university hospitals. The participants of the network have shown a high 
degree of willingness to share workflows, data, and general knowledge to 
enable the development, standardization, and implementation of standard 
workflow. More than 35 people participated in the 10 workshops from the 
four Danish university hospitals. At the last meeting, the network was expan-
ded to cover the National Genome Center and ELIXIR Denmark. Furthermore, 
the network has established common bioinformatics standards that are now 
largely in place at all university hospitals. The group has published more than 
20 peer-reviewed papers on biomarker development and a prototype of a 
searchable database has been developed and deployed in the North Denmark 
Region’s IT infrastructure.
The project has had an impact on Danish health care and the research infra-
structure, as the experience from the network build-up was used in the wor-
king groups of the newly established Danish National Genome Center. Two 
networks supported by the Danish Comprehensive Cancer Center (DCCC) plan 
to use the infrastructures of NEXT Bioinformatics – one focused on somatic 
variant interpretation and one on establishing a basket trial for treatment 
of refractory cancer, as well as one ‘Knæk Cancer’ project on acute myeloid 
leukaemia. 
It was also possible to attract additional funding for NEXT Bioinformatics. For 
example, DCCC provided DKK 175,000 for consolidating “the national network 
of clinical bioinformaticians” and AAU’s Digital Hub Denmark donated DKK 
200,000 of seed money to facilitate the formulation of a larger application for 
funding the development of decision support tools for personalized medici-
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ne based on NEXT Bioinformatics competences. The DCCC network funded a 
national bioinformatics network workshop on November 12 and 13, 2018 in 
Skagen and a Broad Institute GATK4 Best Practices workshop on January 29 – 
February 1, 2019 in Copenhagen. 
Critical assessment of the work
A drawback of the work is that the searchable variant database is not yet 
implemented on a national level and the common standards are not fully 
implemented or accredited in a clinical setting. However, there are good re-
asons for this. The decision to develop a database was made by the steering 
committee during the project period, detracting focus from common stan-
dards and biomarker development. The prototype for clinical data collection 
is not suitable for scaling as it requires much manual work; however, work is 
in progress to integrate data collection with medicine registries and patient 
administrative systems. 
Comparison with other initiatives
There are other initiatives, but limited information is available. We are not 
aware of any successful extensive data sharing of somatic variants paired 
with clinical data. This is probably because other nations’ health care systems 
are based on insurance models, causing big cancer centres with genome me-
dicine to “fight” each other for patients, insurance money, and fame. This 
starkly contrasts the Scandinavian health care models with one public health 
care payer. This provides Denmark and the other Scandinavian countries an 
outstanding opportunity to carry the field forward. 
Conclusions and suggestions for future work
Bioinformatics is becoming increasingly important and involved and should 
therefore be handled by sufficiently large groups with critical mass. Based on 
the successful achievements of NEXT Bioinformatics, the participating parties 
have agreed to formally establish a “Danish Society of Clinical Bioinformatics“ 
(DSCB) at the next meeting on May 28, 2019 in Odense. DSCB will be a loosely 
organized group based on a mailing list and simple regulations. The group will 
meet once or twice a year and discuss guidelines for newly developed algo-
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rithms and formulate a funding strategy for national bioinformatics research. 
The difference between DSCB and other societies (e.g., ‘Dansk Selskab for 
Molekylær Medicin’ and ‘Dansk Selskab for Klinisk Genetik’) is its clear focus 
on computational bioinformatics and decision tools for clinical applications. 
DSCB will seek to engage in the formulation of data support centres for each 
region.
The individual regions and the National Genome Center will fund standard 
routine work. However, based on its strong bioinformatics competences, the 
society will apply for external funding for research in decision support tools 
for personalized medicine. We see a great development potential in Denmark 
for studying efficient database construction for variants and patient flows, 
text mining of electronic health records, new bioinformatics standards for 
fast data processing, international data sharing, visualization of patient flows, 
integration with electronic health records, and establishment of clinical evi-
dence.
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